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Introduction: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc)
because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to
assess the safety, efficacy, and molecular change associated with treatment of patients with diffuse cutaneous
(dc)SSc with the TKI nilotinib (Tasigna™).
Methods: Ten adult patients with early dcSSc were treated with nilotinib. Primary endpoints were safety and
change in modified Rodnan Skin Score (MRSS) after 6 months. Lesional skin biopsies at baseline, 6 and 12 months
of treatment were assessed by histopathology, immunohistochemistry, and DNA microarray.
Results: Patients had early and active dcSSc with median disease duration of 0.7 years (range 0.5, 1.7) and increasing
MRSS in the month prior to baseline (mean +2.9, p=0.02). Seven out of ten patients completed 6 and 12 months of
treatment. Seventy-one adverse events (AEs) including 2 serious AEs were observed, and 92 % of AEs were grade 1-2.
Two patients discontinued the medication due to mild QTc prolongation. MRSS improved by a mean of 4.2 points
(16 %) at 6 months and by 6.3 points (23 %) at 12 months in the 7 completers, p=0.02 and 0.01, respectively. Patients
with a decrease in MRSS >20 % from baseline at 12 months (classified as improvers) had significantly higher
expression of transforming growth factor beta receptor (TGFBR) and platelet-derived growth factor receptor beta
(PDGFRB) signaling genes at baseline than non-improvers, and the expression of these genes significantly
decreased in improvers post-treatment.
Conclusion: Nilotinib was well tolerated by the majority of patients in this study, with tolerability limited primarily
by mild QTc-prolongation. Significant MRSS improvement was observed in these early, active patients, but is not
conclusive of treatment effect given the open-label study-design and small number of patients in this pilot study.
Improvers had higher levels of expression of genes associated with TGFBR and PDGFRB signaling at baseline, and a
significant decrease in the expression of these genes occurred only in patients with higher MRSS improvement. The
findings of this pilot study warrant more conclusive evaluation.
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Systemic sclerosis (SSc; scleroderma) is a multisystem
disorder characterized by vasculopathy, autoimmunity,
inflammation, and fibrosis [1]. Patients with diffuse cuta-
neous SSc (dcSSc) have increased morbidity and mortal-
ity when compared to patients with other rheumatic
diseases [2]. Although several medications are used to
treat the skin disease associated with dcSSc, there are no
universally effective therapies, and the treatment of sclero-
derma skin disease remains an area of unmet need [3].
Transforming growth factor beta (TGFB) and the
platelet-derived growth factor (PDGF) are cytokines impli-
cated in the pathological fibrosis of dcSSc [4, 5]. Nilotinib
(Tasigna™; Novartis, Basel, Switzerland) is a tyrosine kinase
inhibitor (TKI) with antagonistic activity against Abelson
tyrosine kinase (c-Abl), the PDGF receptor (PDGFR), and
other tyrosine kinases. It is approved in the USA for the
treatment of chronic myelogenous leukemia (CML) [6]. It
is a therapy of interest for dcSSc because of its ability to
interfere with both TGFB and PDGF signaling. Nilotinib
has been shown to decrease fibrosis in vitro and in bleo-
mycin models of SSc similarly to imatinib [7]. However,
these models have shortcomings in their ability to predict
clinical impact in SSc [8].
Several groups have studied imatinib for the treatment
of dcSSc with variable experiences [9]. Unfortunately,
none of the studies have been definitive due to the
open-label study design, inclusion of patients with lim-
ited cutaneous SSc (lcSSc) and morphea, or inadequate
power [10–13]. Adverse events (AE), in particular fluid
retention, were prominent in these studies, but may be
less frequent when imatinib is used at a low dose [14].
Although fluid retention has been observed in other
populations, it has been particularly problematic in
dcSSc, even leading to the early termination of one trial.
Subcutaneous edema may also elevate the modified
Rodnan skin score (MRSS), as edema can be difficult to
distinguish from dermal thickening.
Nilotinib is a second generation TKI that blocks c-abl
and PDGFR (more potently c-abl than imatinib and less
potently PDGFR) [15]. In populations with CML, edema
has been seen in only 10 % of patients, and this repre-
sents an advantage of nilotinib over imatinib as a candi-




Patients were recruited from November 2010 until
December 2011. Patients fulfilled the 1980 American
College of Rheumatology classification criteria for SSc
[16] and had the diffuse subtype [17]. Patients were over
18 years old, had a disease duration <3 years since the first
SSc-related symptom other than Raynaud’s phenomenon,and had a baseline MRSS ≥16. Patients were excluded
if they had a baseline corrected QT (QTc) interval on
electrocardiogram (EKG) >450 msec. Additional exclu-
sion criteria included treatment with immunosup-
pressive therapies within 3 months before baseline
(including prednisone equivalent >10 mg), pregnancy,
serious medical conditions, diffusion capacity of carbon
monoxide (DLCO) <30 % predicted, or ejection frac-
tion (EF) <50 %.
Study design
This was an investigator-initiated, single-center, open-
label pilot study. The primary objective was to assess the
safety and tolerability of nilotinib in patients with dcSSc
as assessed by the number of AE and serious adverse
events (SAE). The primary efficacy endpoint was change
in MRSS after 6 months of treatment. Secondary efficacy
endpoints included change in MRSS at 12 months,
forced vital capacity (FVC) and DLCO on pulmonary
function testing (PFT) as well as change in the short
form 36 (SF-36) mental (MC) and physical components
(PC) and scleroderma health assessment questionnaire
disability index (SHAQ-DI). Skin biopsies were assessed
using histopathologic and immunohistochemical ana-
lysis, and gene expression profiling with DNA micro-
array to assess change with treatment and explore the
biologic basis of the clinical changes observed.
The protocol was approved by the institutional review
board at the Hospital for Special Surgery. Patients pro-
vided written informed consent before enrollment. An
independent Data and Safety Monitoring Board (DSMB)
regularly reviewed safety data. The trial was registered at
ClinicalTrials.gov (NCT01166139).
Patients were assessed at visits occurring every month
for AE ascertainment, interval history, physical exa-
mination, clinical laboratory measurements, and 12-lead
EKG, and called our center about issues between visits.
AE were listed according to the common terminology of
the National Cancer Institute [18]. AE were graded as
follows: 1 - mild, not requiring intervention; 2 - moderate,
requiring minimal local or noninvasive intervention; 3 -
severe, 4 - life-threatening; 5 - death. AE were attributed
as unrelated, unlikely related, possibly related, probably re-
lated, or definitely related to the study medication in the
opinion of the investigators and as adjudicated by the Data
Safety Monitoring Board (DSMB). The MRSS was mea-
sured at screening, baseline, and every 3 months by the
same physician (RS or JG). PFT with measurement of
FVC and DLCO was performed at baseline and after 6
and 12 months.
Dosing
Patients started nilotinib 200 mg by mouth daily for 1
week, which was up-titrated to 200 mg twice daily for 3
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with measurement of QTc was checked 1 week after any
dosing change. This titration scheme is not required but
was chosen by the investigators to carefully observe any
dose-related side effects [19].
Dermatopathology
Two 3-mm punch biopsies of lesional, extensor-surface,
forearm skin were performed at baseline, and after 6 and
12 months of treatment. The post-treatment biopsies were
taken 1 cm adjacent to the previous biopsy. At each time
point one specimen was formalin-fixed and paraffin-
embedded, and the other was stored in RNAlater (Thermo
Fisher Scientific, Waltham, MA, USA). Sections for histo-
pathology were stained with hematoxylin and eosin (H&E),
anti-α-smooth muscle actin (αSMA), and Masson trichrome
(TC), CD-34, pro-Collagen (proCol), phosphorylated cAbl
(p-cAbl), and phosphorylated PDGFR (p-PDGFR) using
standard techniques. A dermatopathologist (CM), blinded to
treatment status, compared each case. Slides were scored
semiquantitatively using a scale (0, 1, 2, 3) based on collagen
density and degree of infiltrate on H&E, and the intensity of
immunohistochemical stains. Skin thickness was measured
by a micrometer from the epidermis to the subcutis. Eccrine
coils and hair follicles were counted per section.
Gene expression by DNA microarray
Tissue samples stored in RNAlater were homogenized and
RNA was purified as previously described [20]. RNA integ-
rity was assessed using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA) and all sam-
ples had RNA integrity numbers (RIN). Total RNA (25 ng)
was amplified and labeled with Agilent Low Input Quick
Amp Labeling Kit. cRNA was hybridized to Agilent Sure-
Print G3 Human Gene Expression 8x60K Microarrays
(G4851A). Agilent Feature Extraction Image Analysis Soft-
ware (Version 10.7.3) was used to extract data from raw
microarray image files. Microarray data were log2-lowess
normalized and filtered for probes with intensity ≥1.5-fold
over local background in Cy3 or Cy5 channels. Expression
values were multiplied by −1 to convert them to log2(Cy3/
Cy5) ratios. Probes with >20 % missing data were excluded
resulting in 31,762 probes that passed the filtering criteria.
Paired samples (baseline and post-treatment biopsies at 12
months) were available for six patients and were used for
analyses. We categorized patients as improvers based on a
decrease in MRSS of >20 % at 12 months compared to
baseline, and 4/6 patients with paired 12-month biopsy
specimens met this criterion. The expression data from the
study are deposited to NCBI GEO [GEO:GSE65405].
Microarray data pre-processing
Microarray data were pre-processed and analyzed using
GenePattern modules [21] with default parameters unlessstated otherwise. Expression data in Stanford preclustering
(PCL) file format were converted to Gene Cluster Text
(GCT) file format via PclToGct module. Missing expres-
sion values were imputed via ImputeMissingValuesKNN
module. In total, 31,762 probes were collapsed to 18,398
unique gene symbols via CollapseDataset module using
annotation file for the Agilent 8x60K microarray platform.
Class label (CLS) files were created via ClsFileCreator
module to define phenotypic classes for microarray sam-
ples. Expression data were median-centered gene-wise in
Cluster 3.0 [22].
Differential expression analysis
For both baseline (improvers vs non-improvers) and im-
prover (baseline vs post treatment) comparisons, the
ComparativeMarkerSelection [23] module from Gene-
Pattern was used to identify differentially expressed genes.
The ‘number of permutations’ parameter was set to 0 and
the ‘log transformed data’ parameter was set to ‘yes’. For
improver comparison, the ‘test statistic’ parameter was set
to ‘Paired T-Test’. Expression data for significant genes
(p <0.05, not corrected for multiple hypothesis testing)
were extracted via the ExtractComparativeMarker-
Results module and converted to PCL file format using
the GctToPcl module. Expression data were then hier-
archically clustered gene-wise and array-wise in Cluster
3.0 using the uncentered correlation similarity metric and
average linkage clustering method, and were visualized in
TreeView [24].
Pathway enrichment analysis
For baseline and improver comparisons, pathways with
significant changes in expression were identified by gene
set enrichment analysis (GSEA) [25, 26] and single-sample
GSEA (ssGSEA) [27] using corresponding GenePattern
modules. All GSEA analyses were corrected for multiple
hypothesis testing. GSEA and ssGSEA were run against
the Canonical Pathways database comprising gene sets
from several pathway databases. For GSEA, the ‘permuta-
tion type’ parameter was set to ‘gene set’. ssGSEA enrich-
ment scores were normalized by dividing by the
maximum ssGSEA enrichment score for this expression
dataset. Normalized ssGSEA enrichment scores for sig-
nificant pathways (false discovery rate (FDR) <5 %)
were extracted, clustered and visualized as described
above for the expression data.
Intrinsic subset assignment
Intrinsic probes (n = 995) from Milano et al. [28] were
collapsed to 793 unique genes. Separately the entire nilo-
tinib dataset comprising expression data for 24 samples
(including all baseline, 6-month and 12-month biopsies)
was combined with 4 healthy control samples analyzed
on the same DNA microarray platform to provide the
Table 1 Baseline characteristics
Variable Value
Age, years, median (range) 46 (18−69)
Sex, female, n (%) 8 (80 %)
Race, n (%)
Caucasian 5 (50 %)
African American 3 (30 %)
Disease duration, median (range) 0.7 (0.5−1.7)
ANA-positive, n (%) 9 (90 %)
Anti-Scl 70-positive, n (%) 3 (30 %)
RNA polymerase III-positive, n (%) 5 (50 %)
MRSS at baseline, mean ± SD 30.1 ± 8.2
Mean change in MRSS in 1 month
prior to baseline, mean ± SD
+2.9 ± 3.4
Tendon friction rubs, n (%) 4 (40 %)
Previous treatment, n (%)
Methotrexate 2 (20 %)
No immunosuppression 8 (80 %)
ANA antinuclear antibody, MRSS modified Rodnan skin score
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ples 27,276 probes passed quality filters and were col-
lapsed to 16,580 unique genes. Overlap with the 793
unique genes from Milano et al. resulted in 651/793
genes (82.1 %) in common between the two datasets.
These 651 genes were used to organize the gene expres-
sion data from nilotinib and healthy control samples by
unsupervised hierarchical clustering.
Intrinsic subset assignment was performed using the 651
intrinsic genes to calculate Spearman non-parametric sta-
tistics (correlation coefficients and p values) between each
sample from the study and three centroids corresponding
to fibroproliferative, inflammatory and normal-like samples
from Milano et al. Limited was excluded because no lim-
ited SSc samples were included in this study. Centroids
were created by averaging expression values for each gene
across all samples assigned to a given intrinsic subset in
Milano et al. The intrinsic subset assignment for each nilo-
tinib sample was to the subset centroid with the highest
Spearman correlation coefficient and the lowest p value.
Statistical analysis
Descriptive analysis of AE and SAE was performed for
assessment of clinical data. Continuous clinical variables
were analyzed using the unpaired (baseline vs baseline)
and paired (baseline vs post treatment) t test.
For gene expression analysis, the relationship between
baseline intrinsic subset and response status was ana-
lyzed using the chi-square test. In cases where three or
more groups were compared, one-way analysis of vari-
ance (ANOVA) was used and p values were corrected
for multiple testing using Tukey’s multiple comparisons
test with a single pooled variance. Statistical analyses
were performed using SPSS software version 17.0 (IBM,
Armonk, NY, USA) and GraphPad Prism Windows 6.05
(GraphPad Software, San Diego, CA, USA).
Results
Patients
Nineteen patients were screened for study inclusion. Five
were excluded due to baseline QTc >450 msec and four
were excluded due to meeting other exclusion criteria.
Baseline characteristics of all patients are listed in
Table 1. The patients in this study represented a group
of patients with early and active dcSSc. The median dis-
ease duration based on the time since the first non-
Raynaud’s symptom of SSc was 0.7 years (range 0.5−1.7).
In the 1-month screening period prior to starting medica-
tion, 70 % patients had an increasing MRSS, and the
group had a mean MRSS increase of 2.9 points, p = 0.02.
Fifty percent of patients were positive for the RNA Poly-
merase 3 antibody. Seven patients tolerated 6 months of
nilotinib and continued treatment for at least 12 months.
Two patients had to discontinue nilotinib within the firstmonth due to grade 1 (QTc of 453 msec) or 2 (QTc of 483
msec) QTc prolongation. One patient discontinued due to
progression of preexisting coronary artery disease after 3
months of treatment.
Adverse events
Seventy-one AE including two SAE were observed dur-
ing the 12-month treatment period (Additional file 1);
75 % were considered to be at least possibly related to
nilotinib (Table 2). Of the AE, 92 % were grade 1 or 2
and no unexpected events were observed. One common
AE was grade 1 (<2.5 × upper limit of normal) liver
function test (LFT) abnormality, which occurred in 50 %
of patients. All LFT abnormalities are shown in
Additional file 1, and all were asymptomatic. No medica-
tion adjustment was necessary and the abnormal values
resolved when the laboratories were rechecked. There
were no LFT abnormalities of grade 2 or higher. QTc pro-
longation occurred in 60 % of patients. Although QTc
prolongation was grade 1 or 2, our protocol required dis-
continuation of two patients due to this. The other four
patients had normalized QTc on repeat EKG or adjust-
ment of medication dosage.
Two SAEs occurred both of which were considered
possibly related to the medication. One patient ex-
perienced a syncopal episode and was hospitalized. The
medication was held and the patient’s evaluation, includ-
ing EKG with QTc measurement and telemetry, was nor-
mal with the syncopal episode considered to be a vasovagal
episode. However, when the patient followed up and off
medication for 3 weeks, her baseline was QTc >450 msec
and she could not restart medication as she now met an
Table 2 Adverse events
Adverse event Number of patients
reporting adverse events
Grade
Blood and lymphatic system disorders
Anemia 3 1
Decreased WBC count 1 1
Cardiac disorders
Prolonged QTc 6 1, 2











Elevated total bilirubin 5 1
Increased AST 5 1
Increased ALT 4 1
Increased amylase 2 1
Increased lipase 2 1
Metabolism and nutrition disorders
Low inorganic phosphorus 1 1





Concentration impairment 1 1
Reproductive system and
breast disorders
Erectile dysfunction 1 1
Skin and subcutaneous
tissue disorders
Rash acneiform 1 2
Alopecia 1 1
All AEs considered at least possibly related to nilotinib are listed in order of
frequency and by Common Terminology Criteria for Adverse Events (CTCAE)
grade. WBC white blood cells, QTc corrected QT interval, AST aspartate
aminotransferase, ALT alanine aminotransferase
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history of coronary artery disease (CAD) was hospitalized
for coronary artery bypass graft (CABG) surgery after 3
months of treatment. The patient had multiple risk factors
for vascular disease including age, diabetes mellitus,
longstanding essential hypertension, hyperlipidemia, andobesity. She had atypical chest pain, which she described as
heartburn and which had been attributed to her gastro-
esophageal reflux disease predating the trial. She under-
went cardiac testing during the trial, which in turn led to
indication for CABG. It is possible that worsening of her
vascular disease was related to nilotinib use, although with
her multiple risk factors and symptoms that predated




In the seven patients who completed 12 months of treat-
ment, the MRSS statistically significantly improved from
a mean of 26.9 ± 5.4 to 22.7 ± 8 (by 16 %) at 6 months
and to 20.6 ± 7.7 (by 23 %) at 12 months, p = 0.02 and
0.0112, respectively (Table 3). The mean change in the
MRSS in the completers with the RNA Polymerase3
antibody (n = 4) was −7.0 ± 1.8 versus −5.5 ± 7.5 in
those without (n = 3). This was not statistically signifi-
cant, p = 0.68.
Two patients who discontinued study medication had
follow-up MRSS at 6 months. One patient’s MRSS de-
creased from 43 to 21 on 4 months of mycophenolate,
after stopping nilotinib after less than 1 month due to
QTc prolongation. One patient’s MRSS was relatively
unchanged from 44 to 46 after stopping nilotinib after 3
months. The third patient continued her care locally.
Pulmonary efficacy
Out of 10 patients, 3 had ILD at baseline and 2 of those
patients did not complete the study. The mean FVC was
77.4 ± 12.9 % predicted at baseline, 75.4 ± 12.6 % at 6
months and 71.7 ± 11.7 at 12 months, p = 0.17 and
0.054, respectively. The DLCO was 72.0 ± 9.9 % pre-
dicted at baseline and 69.9 ± 18.1 % at 6 months, and
69.3 ± 12.4 % at 12 months, p = 0.56 and 0.25, respect-
ively. The completer with ILD had stable PFT parame-
ters. The trend to decline in FVC was driven by one
patient without evidence of ILD at entry, who went on
to develop mild reticular opacities after one year.
Other assessments
The physician global assessment (PGA) significantly im-
proved from 62.5 ± 10.8 at baseline to 40.2 ± 12.7 at 6
months, and to 32.3 ±15.3 at 12 months, p = 0.0033 and
0.0013, respectively. There were no significant differences
in ESR, SHAQ-DI, SF-36 mental or physical components,
oral aperture, hand extension, or finger-to-palm distance.
Dermatopathologic assessment
Eight patients had biopsies at baseline and 6 months and
six patients had biopsies at 12 months. The mean skin
thickness at baseline was 2.3 ± 0.6 mm, 2.7 ± 0.6 mm at
Table 3 Clinical outcomes in completers (n = 7)




MRSS 26.9 ± 5.4 22.7 ± 8 20.6 ± 7.7 0.02 0.01
FVC 77.4 ± 12.9 75.4 ± 12.6 71.7 ± 11.7 0.17 0.054
DLCO 72.0 ± 9.9 69.9 ± 18.1 69.3 ± 12.4 0.56 0.25
PGA 62.5 ± 10.8 40.2 ± 12.7 32.3 ±15.3 <0.01 <0.01
SHAQ 0.71 ± 0.34 0.79 ± 0.59 0.86 ± 0.66 0.86 0.74
ESR 17.2 ± 14.5 23.0 ± 22.1 22.6 ±17.7 0.19 0.1506
SF-36 MC 51.5 ± 8.2 52.8 ± 7.6 52.1 ± 5.6 0.74 0.90
SF-36 PC 43.1 ± 9.5 40.3 ± 9.5 41.7 ± 9.1 0.37 0.74
MRSSmodified Rodnan skin score, FVC forced vital capacity, DLCO diffusion lung capacity of carbon monoxide, PGA physician global assessment, SHAQ scleroderma
health assessment questionnaire, ESR erythrocyte sedimentation rate, SF-36 MC short form-36 health survey mental component, SF-36 PC short form-36 health survey
physical component
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tistically significant difference (p = 0.06 at 6 months and
p = 0.36 at 12 months). One patient sample is shown in
Fig. 1. There was no significant change in the group in
collagen density, degree of infiltrate on H&E, number of
follicles and eccrine structures, and staining intensity of
α-SMA, trichrome, CD-34, pro-Collagen, p-PDGFR, or
p-cAbl; these data are summarized in Additional file 2.
There was no difference in qualitatively assessed staining
of pPDGFR or p-cAbl staining between those patients
with MRSS improvement >20 % and those who did not
meet this level of improvement.Fig. 1 Photomicrographs of forearm skin biopsy from one patient as studie
actin (α-SMA) at 0 (c) and 12 (d) months of treatment. This specimen demo
thickness of collagen bundles and increased interstitial space between the
as well. However, when looking at all of the specimens overall, significant mGene expression changes in skin
Intrinsic gene expression subset assignment before and
after treatment
We used intrinsic subset genes from Milano et al. [28]
(see Methods and Additional file 3) to assign the sam-
ples in this trial to intrinsic gene expression subsets
(Fig. 2a). Subsets were assigned based on Spearman cor-
relation statistics to a gene expression centroid calculated
from Milano et al. samples (see Methods and Additional
file 4). Clustering was primarily driven by a strong inflam-
matory signature evident in the skin of these patients
(Fig. 2b). Baseline intrinsic subset assignment showed thatd by H&E at 0 (a) and 12 (b) months and by alpha smooth muscle
nstrates morphological improvement as evidenced by decreased
collagen bundles. Decreased intensity α-SMA is seen in this specimen
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Fig. 2 Intrinsic subset assignment. a Nilotinib sample tree: green normal-like, red fibroproliferative, purple inflammatory intrinsic subset samples,
based on the expression patterns of intrinsic genes. Square brackets indicate samples from the same patient. b Heat map of intrinsic genes. The
intrinsic subset row refers to subset assignments based on Spearman correlation statistics
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fibroproliferative at baseline (two inflammatory and one
normal-like), whereas one improver was classified as
fibroproliferative. The patients who improved generally
lost their major subset signature and three out of four
were classified as normal-like post treatment (Table 4).
The two non-improvers were assigned to the fibroproli-
ferative subset (p = 0.0833, chi-square test for enrichment
of fibroproliferative patients as non-improvers) and
remained in the fibroproliferative subset post treatment,
consistent with the results of Pendergrass et al. [29].
Slight discrepancies between the Spearman correlation
intrinsic subset assignments and the hierarchical clus-
tering tree occured mainly in post-treatment samples.TGFBR and PDGFRB signaling pathways are highly
expressed in improvers at baseline
We performed differential gene expression analysis be-
tween baseline improver (n = 4) and non-improver (n = 2)
samples (Fig. 3a): 2,242 genes were significantly diffe-
rentially expressed at baseline (p <0.05, unpaired t test)
(Fig. 3b).
We used GSEA to identify 18 pathways with signifi-
cantly differential expression between improvers and non-
improvers (FDR <5 %; corrected for multiple testing).
Pathways that increased in improvers included TGFB
receptor signaling (TGFBR) and nuclear factor kappa B
(NFKB) signaling, whereas pathways with increased ex-
pression in non-improvers included telomere maintenance
and meiosis, suggesting enrichment in terms associated
with the cell cycle and cell proliferation, consistent with
the assignment of the two non-improvers to the fibropro-
liferative subset (Fig. 3c).
The four improvers with baseline and 12-month biop-
sies were included in the microarray data analysis
(Fig. 4a). We identified 666 genes significantly differen-
tially expressed in improvers between baseline and post
treatment (p <0.05, paired t test) that comprised an
improver gene signature (Additional file 5). Genes that
showed decreased expression post treatment included
TGFB-regulated (SMAD2, ACTB, COL15A1, ABI1, EGR2
and EGR3) and inflammatory (SIGLEC7, IL23A, ICAM1,Table 4 Instrinsic subset assignments in completers with at
least two skin biopsies
Patient Response Baseline subset Post-treatment subset
N5 Improver Inflammatory Fibroproliferative
N10 Improver Fibroproliferative Normal-like
N11 Improver Inflammatory Normal-like
N16 Improver Normal-like Normal-like
N15 Non-improver Fibroproliferative Fibroproliferative
N19 Non-improver Fibroproliferative FibroproliferativeCCL2 and MMP14) gene signatures (Fig. 4b, Additional
file 5). These genes had significantly higher expression
in improvers at baseline relative to non-improvers,
and were significantly decreased in improvers post
treatment (p <0.0001 for both comparisons). In con-
trast, their expression remained stable in non-
improvers (p = 0.1057) (Fig. 4c). Non-improvers had
74 genes with significant differential expression be-
tween baseline and post-treatment samples, and no
significant overlap with the improver signature. There
were only 2/74 genes in common with the improver
gene signature but their directionality was opposite to
that for improvers.
We identified 25 pathways that were highly significantly
decreased in improvers post-treatment (FDR <1 %), in-
cluding multiple immune response pathways such as
interleukin and interferon signaling (Fig. 4d). A broader
list of 106 pathways that were significantly decreased in
improvers post treatment (FDR <5 %) is shown in
Additional files 6 and 7. We were interested in TGFBR
and PDGFRB pathways because of their relevance to fi-
brosis in SSc and their convergence on c-Abl, a target of
nilotinib. We identified 19 genes involved in TGFBR sig-
naling (including TGFB2, TGFB3, TGFBR1 and TGFBR2)
and 50 genes involved in PDGFRB signaling (including
PDGFRB and PDGFB) that comprised the core enrich-
ment groups for these pathways in improvers based on
GSEA results (Additional file 8).
We examined the expression of TGFBR and PDGFRB
signaling gene sets across six completers (combined im-
provers and non-improvers), four improvers and two
non-improvers at baseline and post treatment (Fig. 5).
Both pathways were significantly higher at baseline in
improvers compared to non-improvers (p <0.0001 for
both gene sets). Both pathways significantly decreased post
treatment in improvers (p <0.0001 for both gene sets).
While genes associated with TGFBR signaling showed
stable expression in non-improvers (p = 0.1092) (Fig. 5a),
PDGFRB signaling genes were significantly increased in
non-improvers post treatment (p = 0.0058; Fig. 5b). No
pathways were significantly differentially expressed in sam-
ples from non-improvers at baseline and post-treatment.
Discussion
The initial positive in vitro and murine studies on the
use of TKIs with c-Abl and PDGFR inhibition (e.g., ima-
tinib, nilotinib, and dasatinib) for dcSSc presented the
hope for a profound treatment effect for the cutaneous
fibrosis seen in dcSSc. Several studies have attempted to
address the safety and effectiveness of imatinib in this
population, but design limitations make it impossible to
make definitive conclusions. The collective imatinib ex-
perience has been mixed. A modest improvement in skin
thickening was seen in some open-label studies, but side
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Fig. 3 Baseline differential gene expression and pathway enrichment analysis. a Baseline sample tree: blue improvers, orange non-improvers. b Sample
genes differentially expressed at baseline between improvers and non-improvers. c Pathways differentially expressed at baseline between improvers
and non-improvers
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(See figure on previous page.)
Fig. 4 Improver differential gene expression and pathway enrichment analysis. a Improver array tree: blue baseline samples, black post-treatment
samples. b Sample genes differentially expressed in improvers between baseline and post-treatment biopsies. c Improver gene signature trends
across improver and non-improver samples. Graphs represent Tukey box and whiskers plots. d Pathways differentially expressed in improvers
between baseline and post-treatment biopsies
Gordon et al. Arthritis Research & Therapy  (2015) 17:213 Page 11 of 14effects, especially fluid retention, were prevalent and
prevented some patients from continuing the medica-
tion. This paper is the first published report on the use
of nilotinib for the treatment of dcSSc.
In this pilot study of nilotinib, a different but related
TKI with fewer fluid-related side effects, our goals were to
assess safety in a population with dcSSc, generate pilot
data on the MRSS to help us adequately power future
studies, and to use histopathology and gene expression
profiling to further understand our clinical observations.
Nilotinib was well-tolerated by the majority of patients
in this study. Although the number of AE that were at
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Fig. 5 Transforming growth factor beta receptor (TGFBR) and
platelet-derived growth factor receptor beta (PDGFRB) signaling
trends across nilotinib patients. a Expression trends for TGFBR signaling
pathway across completers, improvers and non-improvers. b Expression
trends for PDGFRB signaling pathway across completers, improvers and
non-improvers. Scatter plots show mean with standard deviationAE represented asymptomatic laboratory abnormalities
that resolved without intervention. The side effects ob-
served were similar to what has been seen in patients
with CML [30, 31]. However, nilotinib is known to have
important cardiovascular side effects, which were ob-
served and are particularly relevant to SSc patients.
Monitoring the QTc with periodic EKG is required.
Conduction abnormalities including QTc prolongation
can be seen in dcSSc patients [32] or as a side effect of
other medications they may use. In our study QTc
prolongation was seen in five SSc patients at screening,
which limited their eligibility. Persistent mild QTc
prolongation without arrhythmia was the cause of two
patients discontinuing treatment. Acceleration of peri-
pheral arterial vascular disease has been reported with
nilotinib in CML patients both with and without other risk
factors for CAD [33, 34]. In this small study we observed
exacerbation of preexisting CAD in one patient with other
risk factors. Careful consideration of the use of this medi-
cine in patients with CAD or multiple risk factors would
be needed in patients with SSc, as it would in CML.
We observed that the MRSS improved in a statistically
significant manner with 6 and 12 months of treatment
in this group of patients with very early and active SSc.
The range of the minimally clinically important dif-
ference in MRSS has been estimated to be 3.2−5.3 points
[35]. Therefore, the patients in this study were observed
to change in a clinically meaningful manner. At the time
of study entry the median disease duration was 0.7 years,
70 % of patients had a worsening MRSS, 50 % had the
RNA Polymerase3 antibody and 40 % had tendon fric-
tion rubs. The combination of these clinical attributes
put these patients at high risk of exacerbation of disease
during the study period. However, the MRSS improve-
ment is inconclusive given the uncontrolled study design
and the observation that the MRSS tends to improve
both with time [36] and in the context of clinical trials
[37]. Nonetheless, this clinical finding of improved
MRSS in group of patients with such early and active
dcSSc is worthy of further and more definitive study.
The FVC and DLCO were not significantly changed,
but our trial was not designed to evaluate pulmonary
endpoints, and most patients in this study did not have
ILD. Recently another TKI, nintedanib, which has some
overlapping spectrum of TK inhibition, has been shown to
slow the decline of FVC in idiopathic pulmonary fibrosis,
a related fibrotic condition [38]. The additional outcome
measures, including the SF-36 and SHAQ, at the 6- and
Gordon et al. Arthritis Research & Therapy  (2015) 17:213 Page 12 of 1412-month time points also remained stable, and this has
been shown to occur typically in SSc clinical trials [39].
In this study we used gene expression profiling and
the concept of SSc intrinsic subsets to characterize bio-
logical response and distinguish between nilotinib im-
provers and non-improvers. In terms of the intrinsic
subset assignment, three of four improvers were classified
as non-fibroproliferative (with two out of four classified as
inflammatory), whereas non-improvers were classified as
fibroproliferative at baseline. Improvers tended to lose
their intrinsic subset signature and become normal-like
post treatment, while non-improvers remained fibroproli-
ferative (Table 4). Genes from specific pathways targeted
by nilotinib (e.g., TGFBR and PDGFRB signaling) showed
significantly higher expression in improvers at baseline
and were significantly downregulated in those improvers
by treatment, whereas their expression in non-improvers
was stable or displayed directionality opposite to im-
provers, with low expression at baseline. Interestingly, a
recent analysis of imatinib and nilotinib effects in SSc
mouse models suggested that high activation status and
expression pattern of TKI targets was predictive of the po-
tential response to therapy [8]. It is not clear based on this
single-group and uncontrolled clinical trial whether our
results represent the natural history of the disease or a
treatment effect, although an apparent change in the post-
treatment intrinsic subset assignment to the one with less
severe disease in improvers might reflect beneficial effects
of the therapy. As the use of gene expression in the con-
text of clinical trials continues, the significance of these
findings will be more conclusive.
In this study, we found that TGFBR signaling was sig-
nificantly increased in improvers at baseline and that this
signature spanned the inflammatory and fibroproliferative
subsets. In our original study of TGFB signaling in SSc
skin [40] we observed its enrichment primarily in the
fibroproliferative subset. However, a recent meta-analysis
of three independent gene expression datasets from SSc
skin, which dramatically increases the number of samples
analyzed, shows that TGFBR signaling appears to span the
inflammatory and fibroproliferative subsets [41, 42].
The results here are consistent with those data, as our
improvers, who are primarily defined by high expression
of TGFBR signaling at the initiation of treatment, appear
to span across the fibroproliferative and inflammatory in-
trinsic gene expression subsets. This indicates that a bio-
marker of TGFBR signaling will be a useful stratification
method in addition to biomarkers of the intrinsic gene ex-
pression subsets.
The histopathology of the forearm skin biopsy did not
show a significant morphological improvement even in
cases where a clinical improvement was seen, and
phospho-staining of known targets of nilotinib in the skin
was not differentially activated before and after treatment.It is possible that these dermatopathological investigations
are less sensitive than microarray in picking up this degree
of change, and this would be a topic for future
investigation.
There were several limitations to this study, including
its open-label design and small sample size. Because of
these factors conclusions about efficacy cannot be defini-
tively drawn. As noted, the MRSS tends to improve due
to regression to the mean [35] and in the context of clin-
ical trials [36]. The lack of a control group additionally
makes the changes in gene expression observed in the
microarray studies inconclusive with respect to whether
they represent a change due to treatment or a change
based on the natural history of the disease. In terms of
the differential gene expression analyses, we had to use
uncorrected p values in the unpaired and paired t tests
as the small sample size precluded the adjustment for
multiple comparisons. We controlled for this by focus-
ing on pathways found to be deregulated using GSEA,
which were corrected for multiple hypothesis testing.
This was a pilot study designed to provide preliminary
data that could drive more conclusive hypothesis testing.Conclusions
This was an open-label, single-group pilot trial, which in-
cluded histopathologic and microarray analyses of skin to
further delineate biological response. In this pilot clinical
trial a significant improvement in the MRSS was observed
in patients who would have been expected to have pro-
gression of disease. Seventy percent of patients were able
to tolerate the medication for 12 months, and side effects
were predictable. Improvers were most clearly defined by
having high expression of genes associated with TGFBR/
PDGFRB signaling at the time of treatment initiation,
while those that did not improve did not have evidence of
activation. TGFBR and PDGFRB signaling pathways sig-
nificantly decreased in improvers post treatment and this
was not observed in non-improvers. Further evaluation of
nilotinib or related TKIs in a randomized and controlled
setting is warranted.Additional files
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